Clinical Trial Type: Solid Tumor

Description:  Advanced Solid Tumors:   ABBV-400 as Monotherapy-A Global First-in-Human Study     Target Patient Population: All solid tumors   Study Design: Study drug is administered IV every 3 weeks   For more information on this trial, read its profile on clinicaltrials.gov here.

C-1400-01 (AGEN1777) (Agenus, Inc.) Description:  A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination with PD-1 Inhibition in Patients With Advanced Solid Tumors Target Population:  All solid tumors.  To be given as single agent or in combination with Balstilimab Study Design:  Study drug is administered IV every 3 weeks.  

Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

ALPN-202 – NEON-2 (Alpine Immune Sciences)  Description:  An open-Label Study of ALPN-202 Combined With PD-1 Inhibition In Subjects With Advanced Malignancies (NEON-2) Target Patient Population:.  All solid tumors Study Design: Study drug is administered IV every 1 or 3 weeks  

BBI-20201001 (Bolt) Description:   Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2-Expressing Solid Tumors Target Patient Population: Advanced solid tumor patients with IHC 2+/3+/or Her2 amp on NGS/FISH/CISH.  Study Design:  Study Drug will be administered IV every 3 weeks. 

CA115-001 (Bristol Myers Squibb)  Description:   Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small cell Lung Cancer Target Patient Population: Starting with dose escalation in advanced solid tumors with specific cohorts in combination with Nivolumab Study Design:  Study Drug will be administered IV

CLN-619-001  (Cullinan) Description:  A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors  Target Patient Population:  All solid tumors.  Monotherapy arms and combination arms administered with Pembrolizumab Study Design:  Drug is administered IV weekly in

Debio 0123-102 (Debiopharm) Description:  A Phase 1, Dose Finding Study of Debio 0123 as Monotherapy in Adult Patients with Advanced Solid Tumors, followed by an Expansion Part to Assess Safety and Preliminary Anti-Tumor Activity   Target Patient Population:  All solid tumors in Dose Escalation Study Design:  Drug is given orally daily.